The concept of early systemic sclerosis following 2013 ACR\EULAR criteria for the classification of systemic sclerosis

Current Rheumatology Reviews

Volumn 10, Issue 1, 2014, Pages 38-44

  Valentini, Gabriele ^a   Marcoccia, Antonella ^b   Cuomo, Giovanna ^a   Iudici, Michele ^a   Vettori, Serena ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b SANDRO PERTINI HOSPITAL   (Italy)

Author keywords

Classification criteria; Early SSc; Subsetting; Therapeutic perspectives

Indexed keywords

AUTOANTIBODY;

ARTICLE; CAPILLAROSCOPY; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE COURSE; ESOPHAGUS DISEASE; FIBROSING ALVEOLITIS; HUMAN; SCLERODACTYLY; SCLERODERMA; SKIN ULCER; SYSTEMIC SCLEROSIS; TELANGIECTASIA; CLASSIFICATION; COMPLICATION; METABOLISM; RAYNAUD PHENOMENON; SCLERODERMA, SYSTEMIC; TIME;

AUTOANTIBODIES; HUMANS; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; TIME FACTORS;

EID: 84911371386     PISSN: 15733971     EISSN: 18756360     Source Type: Journal    
DOI: 10.2174/1573397110666140404001756     Document Type: Article

References (37)

1. Black CM, Denton CP. Scleroderma and related disorders in adults and children. In: Isenberg DA, Maddison PJ, Woo P, Glass D, Breedveld FC, eds. Oxford textbook of Rheumatology. 3rd edition. Oxford: Oxford University Press, 2004: 872-95.
2. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
3. Valentini G. The assessment of the patient with systemic sclerosis. Autoimmunity Reviews 2003; 2: 370-6.
4. Fries JF, Hochberg MC, Medsger TA Jr, Hunder GG, Bombardier C. Criteria for rheumatic disease. Different types and different functions. The American College of Rheumatology Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1994; 37: 454- 62.
5. Harper FE, Maricq HR, Turner RE, Lidman RW, LeRoy EC. A prospective study of Raynaud phenomenon and early connective tissue disease. A five-year report. Am J Med 1982; 72: 883-8.
6. Kallenberg CGM, Pastoor GW, Wouda AA. The T. Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies. Ann Rheum Dis 1982; 41: 382-7.
7. Gerbracht DD, Steen VD, Ziegler GL, Medsger TA Jr, Rodnan GP. Evolution of primary Raynaud's phenomeno (Raynaud's disease) to connective tissue disease. Arthritis Rheum 1985; 28: 87-92.
8. Fitzgerald O, Hess EV, O'Connor GT, Spencer-Green G. Prospective study of the evolution of Raynaud's phenomenon. Am J Med 1988; 84: 718-26.
9. Kallenberg CG, Wouda AA, Hoet MH, Van Venrooij WJ. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immune blotting. Ann Rheum Dis 1988; 47: 634-41.
10. Luggen M, Belhorn L, Evans T, Fitzgerald O, Spencer- Green G. The evolution of Raynaud's phenomenon: a long term prospective study. J Rheumatol 1995; 22: 2226-32.
11. Hirschl M, Hirschl K, Lenz M, Katzenschlager R, Hutter HP, Kundi M. Transition from primary Raynaud's phenomenonto secondary Raynaud's phenomenon identified by diagnosis of an associated disease Results of ten years of prospective surveillance. Arthritis Rheum 2006; 54: 1974-81.
12. Ingegnoli F, Boracchi P, Gualtierotti R*et al. Prognostic model based on nailfold capillaroscopy for identifying Raynaud's phenomenon patients at high risk for the development of a scleroderma spectrum disorder. Arthritis Rheum 2008; 58: 2174-82.
13. Medsger TA jr. Classification, Prognosis. In:PJ Clements, DE Furst Eds. Systemic Sclerosis. Second Edition. Lippincott Williams & Wilkins. Philadelphia 2004: pages 17-28.
14. Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis 1995; 54: 944-7.
15. Huizinga TW, Machold KP, Breedveld FC, Lipsky PE, Smolen JS. Criteria for early rheumatoid arthritis: from Bayes' law revisited to new thoughts on pathogenesis. Arthritis Rheum 2002; 46: 1155-9.
16. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002; 46: 357-65.
17. van der Helm-van Mil AH, le Cessie S, van Dongen H, Breedveld FC, Toes RE, Huizinga TW. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum 2007; 56: 433-40.
18. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365(23): 2205-19.
19. Fine LG, Denton CP, Black CM, Korn JH, de Cambrugge B. Systemic sclerosis: current pathogenetic concepts and future prospects for targeted therapy (report of a meeting of Physicians and Scientists, Royal Free Hospital, School of Medicine, London). Lancet 1996; 347: 1453-8.
20. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-6.
21. Koenig M1, Joyal F, Fritzler MJ*et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twentyyear prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008; 58(12): 3902-12.
22. van den Hoogen F, Khanna D, Fransen J*et al.Classification Criteria for Systemic Sclerosis: An ACR-EULAR Collaborative Initiative. Arthritis Rheum 2013; 65: 2737-47.
23. Classification and Response Criteria Subcommittee of the American College of Rheumatology Committee on Quality Measures. Development of classification and response criteria for rheumatic diseases [Editorial]. Arthritis Rheum 2006; 55: 348-52.
24. Fransen J, Johnson SR, van den Hoogen F*et al. Items for developing revised classification criteria in systemic sclerosis: results of a consensus exercise. Arthritis Care Res 2012; 64: 351-7.
25. Johnson SR, Fransen J, Khanna D*et al. Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res 2012; 64(3): 358-67.
26. Poormoghin H, Lucas M, Fertig N, Medsger TA Jr. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 2000; 43: 444-51.
27. Valentini G, Cuomo G, Abignano G*et al.Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features. Rheumatology (Oxford) 2011; 50: 317-23.
28. Doria A. Mosca M, Gambari PF, Bombardieri S. Defining unclassifiable connective tissue diseases: incomplete, undifferentiated or both? J Rheumatol 2005; 32: 3-5.
29. Valentini G, Marcoccia A, Cuomo G*et al. Early Systemic Sclerosis: marker antibodies and videocapillaroscopic findings are each associated with distinct clinical, functional and cellular activation markers. Arthritis Res Ther 2013; 29(15): R63.
30. Valentini G, Vettori S, Cuomo G*et al. Early systemic sclerosis: short-term disease evolution and factors predicting the development of new manifestations of organ involvement. Arthritis Res Ther 2012; 14(4): R188.
31. Valentini G, Marcoccia A, Iudici M, Vettori S, Cuomo G. Early Systemic Sclerosis: Marker Autoantibody Positive Patients Have A Faster Pace Of The Disease. Arthritis Rheum 2013; 65 (suppl): S 288.
32. Matucci Cerinic M, Allanore Y, Czirjak L*et al. The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community It is time to cut the Gordian knot and develop prevention or rescue strategy. Ann Rheum Dis 2009; 68: 1377-80.
33. Avouac J, Fransen J, Walker UA*et al.; EUSTAR Group. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis 2011; 70: 476-81.
34. Matucci-Cerinic M, Bellando-Randone S, Lepri G*et al.Very early versus early disease: the evolving definition of the 'many faces' of systemic sclerosis. Ann Rheum Dis 2013; 72: 319-21.
35. Minier T, Guiducci S, Bellando-Randone S*et al., and the EUSTAR co-workers. Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis 2013; Aug 12 [Epub ahead of print]
36. Czirják L, Matucci-Cerinic M. Beyond Raynaud's phenomenon hides very early systemic sclerosis: the assessment of organ involvement is always mandatory.Rheumatology (Oxford) 2011; 50: 250-1.
37. Lepri G, Guiducci S, Bellando-Randone S et al. Evidence for oesophageal and anorectal involvement in very early systemic sclerosis (VEDOSS): report from a single VEDOSS/EUSTAR centre. Ann Rheum Dis. 2014 Jan 28 [Epub ahead of print].